How Congress plans to reel in Bass

Kyle Bass, a prominent hedge fund manager, has recently caused a stir among the pharmaceutical and biotechnology community. He and his entities are engaging in a strategy of using a fairly new process, the inter partes review (IPR), for challenging patents, allegedly to assist in a financial scheme for shorting the patent owner’s stock.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSD trade secrets suit over clinical trail info thrown out by judge

2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.

Americas

Will Mounjaro and Zepbound get their first US generic rival?

30 June 2026 Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.

Americas

Pfizer’s US Paxlovid patent fight turns on a single error

25 June 2026 The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.

More features

LSD trade secrets suit over clinical trail info thrown out by judge

What’s at stake in Australia’s biggest pharma patent appeal in years?

Vinson & Elkins grows West Coast patent and trade secrets bench

Will Mounjaro and Zepbound get their first US generic rival?

King & Spalding continues hiring spree from pre-merged Winston

Merck KGaA agrees $11.3bn deal in major life sciences expansion

Pfizer’s US Paxlovid patent fight turns on a single error

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

How Congress plans to reel in Bass

More on this story

Editor's picks

Editor's picks

More features